Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Why now
Thesis: Conference appearance, no fundamental change
Catalyst to watch: Clinical data updates
Main risk: No new trial or financial data
Why it matters
Conference panel participation is routine disclosure for a clinical-stage biotech.
Details
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today...
Sources
- prnewswire · 2026-09-24 12:00 UTC